These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 12640212)
1. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212 [TBL] [Abstract][Full Text] [Related]
2. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Hägg S; Spigset O; Lakso HA; Dahlqvist R Eur J Clin Pharmacol; 2001 Sep; 57(6-7):493-7. PubMed ID: 11699614 [TBL] [Abstract][Full Text] [Related]
3. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Nozawa M; Ohnuma T; Matsubara Y; Sakai Y; Hatano T; Hanzawa R; Shibata N; Arai H Ther Drug Monit; 2008 Feb; 30(1):35-40. PubMed ID: 18223460 [TBL] [Abstract][Full Text] [Related]
4. Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3. Okubo M; Narita M; Murayama N; Akimoto Y; Goto A; Yamazaki H Hum Psychopharmacol; 2016 Mar; 31(2):83-92. PubMed ID: 26856397 [TBL] [Abstract][Full Text] [Related]
5. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Shirley KL; Hon YY; Penzak SR; Lam YW; Spratlin V; Jann MW Neuropsychopharmacology; 2003 May; 28(5):961-6. PubMed ID: 12644842 [TBL] [Abstract][Full Text] [Related]
6. Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid. Mao M; Skogh E; Scordo MG; Dahl ML J Clin Psychopharmacol; 2012 Apr; 32(2):287-9. PubMed ID: 22388157 [No Abstract] [Full Text] [Related]
7. Variables associated with high olanzapine dosing in a state hospital. Botts S; Littrell R; de Leon J J Clin Psychiatry; 2004 Aug; 65(8):1138-43. PubMed ID: 15323601 [TBL] [Abstract][Full Text] [Related]
14. CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients. Fekete F; Menus Á; Tóth K; Kiss ÁF; Minus A; Sirok D; Belič A; Póti Á; Csukly G; Monostory K Sci Rep; 2023 Oct; 13(1):18507. PubMed ID: 37898643 [TBL] [Abstract][Full Text] [Related]
15. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. Skogh E; Sjödin I; Josefsson M; Dahl ML J Clin Psychopharmacol; 2011 Feb; 31(1):4-9. PubMed ID: 21192135 [TBL] [Abstract][Full Text] [Related]
16. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803 [TBL] [Abstract][Full Text] [Related]
17. Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia. Lu ML; Wu YX; Chen CH; Kuo PT; Chen YH; Lin CH; Wu TH PLoS One; 2016; 11(2):e0148539. PubMed ID: 26849777 [TBL] [Abstract][Full Text] [Related]
18. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication. Theisen FM; Haberhausen M; Schulz E; Fleischhaker C; Clement HW; Heinzel-Gutenbrunner M; Remschmidt H Ther Drug Monit; 2006 Dec; 28(6):750-9. PubMed ID: 17164690 [TBL] [Abstract][Full Text] [Related]
19. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. Lesche D; Mostafa S; Everall I; Pantelis C; Bousman CA Pharmacogenomics J; 2020 Apr; 20(2):192-201. PubMed ID: 31616047 [TBL] [Abstract][Full Text] [Related]
20. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Macias WL; Bergstrom RF; Cerimele BJ; Kassahun K; Tatum DE; Callaghan JT Pharmacotherapy; 1998; 18(6):1237-48. PubMed ID: 9855322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]